Literature DB >> 30719810

Anaplastic large cell lymphoma with TP63 rearrangement: A dismal prognosis.

Takahisa Yamashita1, Morihiro Higashi1, Ryutaro Kawano1, Shuji Momose1, Michihide Tokuhira2, Masahiro Kizaki2, Jun-Ichi Tamaru1.   

Abstract

Anaplastic large cell lymphoma (ALCL) with TP63 rearrangement is a new entity and has the most dismal prognosis in all types of ALCL. This might be due to the resulting fusion protein having N-terminal truncated p63 with high oncogenic ability. Since this N-terminal domain has the function of tumor suppressor activity, the mechanism for high oncogenic capacity is thought to be the dominant negative function. Here, we report two ALCL cases with TP63 rearrangement that was each given too short a prognosis (Case 1 and 2: four and six months) in spite of intensive treatment. Immunohistochemically, p63 was highly expressed, and a sprit signal was detected using a TP63 break apart fluorescence in situ hybridization (FISH) in each case. Additionally, a poor prognostic marker of ALCL, all cytotoxic molecules (TIA-1, Granzyme B, and Perforin) were also expressed in almost all ALCL cells. Taken together, we suggest that not only the dominant negative function of N-truncated p63 but also the effect of cytotoxic molecules may influence the dismal prognosis of ALCL with TP63 rearrangement.
© 2019 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Anaplastic large cell lymphoma (ALCL); FISH; TP63; cytotoxic molecule

Mesh:

Substances:

Year:  2019        PMID: 30719810     DOI: 10.1111/pin.12758

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  1 in total

1.  Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.

Authors:  Takahisa Yamashita; Morihiro Higashi; Shuji Momose; Akiko Adachi; Toshiki Watanabe; Yuka Tanaka; Michihide Tokuhira; Masahiro Kizaki; Jun-Ichi Tamaru
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.